Hemab Therapeutics Holdings, Inc. Common Stock (COAG) Sentiment Analysis
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
- ST sentiment gradeHow the market currently feels about this stock versus its peers
- —
- Overall ST grade
- B+
- ST Score
- 73.5
- Price change today
- —
- Strong buy
- —
- Buy
- —
- Hold
- —
- Sell
- —
- Strong sell
- —
- Bullish share0 bullish vs 0 bearish ratings
- —
Headline tone is a simple keyword scan of recent coverage, not a prediction.
COAG stock: frequently asked questions
What is COAG's ST Score?
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) has an ST Score of 73.5 (B+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is COAG a buy, hold, or sell?
Analysts rate COAG a Buy, with a price target of $51.40 (+50.4% vs the current price). Our ST Score grades it B+ (73.5/100). The ST Score is a data-driven signal, not a recommendation.
What are COAG's factor grades?
Valuation A, Profitability A-, Financial Strength A+, Momentum B-, Growth B-, Forecast B.
What is COAG's valuation grade?
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) earns a valuation grade of A, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is COAG's growth grade?
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) earns a growth grade of B-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is COAG's profitability grade?
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) earns a profitability grade of A-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is COAG's financial strength grade?
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) earns a financial strength grade of A+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for COAG?
The average analyst price target for Hemab Therapeutics Holdings, Inc. Common Stock (COAG) is $51.40 from 3 analysts, which is +50.4% versus the recent price of $34.17.